# Transcrição: Selenium_Mortality_Frontiers_2025

**Arquivo original:** Selenium_Mortality_Frontiers_2025.pdf
**Extraído em:** 2026-02-05 01:35:26 UTC
**Caracteres:** 71507

---

```
                                                                                                                       TYPE Original Research
                                                                                                                       PUBLISHED 28 July 2025
                                                                                                                       DOI 10.3389/fnut.2025.1560167




                                                    Serum selenium and reduced
OPEN ACCESS                                         mortality in middle-aged and
                                                    older adults with prefrailty or
EDITED BY
Samah M. Elaidy,
Suez Canal University, Egypt

REVIEWED BY
Samar Imbaby,
                                                    frailty: the mediating role of
Suez Canal University, Egypt
Weiliang Wang,
Yangjiang Hospital Affiliated to Guangdong
                                                    inflammatory status
Medical University, China

*CORRESPONDENCE                                     Chih-Po Chang 1* and Ching-Hui You 2
Chih-Po Chang
                                                    Division of Geriatric Medicine, Department of Internal Medicine, Mackay Memorial Hospital, Taipei
                                                    1
  chihpo78242002@gmail.com
                                                    City, Taiwan, 2 Chu’s Family Medicine Clinic, Taipei City, Taiwan
RECEIVED 14 January 2025
ACCEPTED 16 June 2025
PUBLISHED 28 July 2025

CITATION                                            Background: Frailty is associated with increased mortality risk among middle-
Chang C-P and You C-H (2025) Serum
selenium and reduced mortality in
                                                    aged and older adults. Selenium, a trace element with antioxidant properties,
middle-aged and older adults with prefrailty        may play a role in reducing mortality by modulating inflammatory processes.
or frailty: the mediating role of inflammatory      This study aimed to investigate the association between serum selenium and
status.
Front. Nutr. 12:1560167.
                                                    mortality in individuals with prefrailty or frailty, with a specific focus on potential
doi: 10.3389/fnut.2025.1560167                      mediators.
COPYRIGHT                                           Methods: Data of participants of National Health and Nutrition Examination
© 2025 Chang and You. This is an                    Survey (1988–1994 and 2011–2016) of the US, aged 40–79 years with serum
open-access article distributed under the
terms of the Creative Commons Attribution           selenium measurements and frailty-related assessments were analyzed. All-
License (CC BY). The use, distribution or           cause and cardiovascular disease (CVD) mortality were confirmed by the
reproduction in other forums is permitted,          National Death Index death certificate data. Systematic inflammation status
provided the original author(s) and the
copyright owner(s) are credited and that the        was surrogated by the systemic immune inflammation index. Multivariable
original publication in this journal is cited, in   Cox proportional hazards models, restricted cubic spline (RCS) analysis, and
accordance with accepted academic                   mediation analysis were used to assess the associations.
practice. No use, distribution or reproduction
is permitted which does not comply with             Results: Among 1,454 participants, those in the second, third, and fourth
these terms.                                        quartiles of serum selenium had significantly lower risks of all-cause mortality
                                                    compared to the lowest quartile. The highest selenium quartile also showed
                                                    a reduced risk of cardiovascular disease (CVD) mortality. Non-linear analysis
                                                    indicated a significant relationship between selenium levels and all-cause
                                                    mortality. Mediation analysis did not reveal that the protective effects of selenium
                                                    were mediated by, CVD, chronic kidney disease, diabetes mellitus, or systemic
                                                    inflammation status [as surrogated by the systemic immune-inflammation index
                                                    (SII)].
                                                    Conclusion: Higher serum selenium levels are linked to a lower risk of all-cause
                                                    and CVD mortality in individuals with prefrailty or frailty. These findings highlight
                                                    the need for future studies to clarify the pathways through which selenium may
                                                    reduce mortality in prefrail and frail populations, and to determine whether
                                                    selenium supplementation could offer therapeutic benefits.

                                                    KEYWORDS

                                                    selenium, frailty, mortality, inflammation, National Health and Nutrition Examination
                                                    Survey (NHANES)




Frontiers in Nutrition                                                    01                                                              frontiersin.org
Chang and You                                                                                                                10.3389/fnut.2025.1560167




Introduction                                                                  Methods
    With increasing life expectancy and declining birth rates,                Study design and data source
population aging has accelerated, drawing attention to age-related
health issues. Frailty and prefrailty are common in middle-aged                   This population-based retrospective cohort study analyzed data
and older adults and are associated with higher risks of falls,               from the publicly released two-year cycles of the US National Health
disability, hospitalization, and mortality (1). Moreover, previous            and Nutrition Examination Survey (NHANES) database. Data from
studies in the US have shown that hospitalization costs for frail             NHANES III (1988–1994) and NHANES 2011–2016 were used to
patients are more than twice those of non-frail patients (2). Frail           performed the analysis.
patients undergoing the same surgical procedures incur                            NHANES data were collected by the National Center for Health
significantly higher median surgery costs, with hospitalization               Statistics (NCHS), a division of the Centers for Disease Control and
expenses increasing by approximately 30% (3). As the global                   Prevention (CDC) of the US. The survey is designed to evaluate the
population continues to age, identifying modifiable factors                   health and nutritional status of adults and children in the US. It uses
that can reduce mortality risk and alleviate healthcare costs in              a complex, multistage design to collect and analyze data representative
these populations has become a priority in public health                      of the national, non-institutionalized US population. The data are
research (4).                                                                 released for research purposes and permission to use the data is
    Frailty and prefrailty in middle-aged and older adults result from        granted to researchers by the NCHS. Participants in NHANES
cumulative physiological decline driven by biological aging, including        complete a household interview and are invited for an extensive
chronic inflammation, hormonal dysregulation, and mitochondrial               examination in a NHANES mobile examination center (MEC),
dysfunction (5). These intrinsic changes are compounded by                    including a physical examination, specialized measurements, and
sarcopenia, multimorbidity, and nutritional deficiencies, leading to          laboratory tests. Consequently, an evaluation of participants in the
diminished physical resilience. Physical inactivity and psychosocial          NHANES database is reliable and multidimensional and can
stressors, such as depression and social isolation, further accelerate        be equated to a population-level assessment (16, 17).
the loss of functional capacity (6). Gender differences and
socioeconomic disparities also influence vulnerability to frailty
through varied exposure to risk factors and access to healthcare.             Ethics statement
Therefore, frailty emerges as a multifactorial syndrome rooted in both
biological deterioration and modifiable lifestyle and environmental               The NCHS Research Ethics Review Board reviewed and approved
factors (7).                                                                  NHANES, and all survey participants provided signed informed
    Selenium is an essential trace element and incorporated into              consent to participate. Therefore, no further ethical approval and
selenoproteins, like glutathione peroxidases (GPx), thioredoxin               informed consent were required to perform the secondary analyses
reductases, and selenoprotein P, which have critical antioxidant,             undertaken in this study. Additionally, all NHANES data released by
detoxication, anti-inflammatory, immune-modulatory, and anti-                 the NCHS are de-identified and all patient data remain anonymous
cancer functions (8). The normal serum selenium levels in adults              during data analysis.
typically ranges from 120–160 (μg/l) (9). Clinical studies have
demonstrated that lower serum selenium levels are significantly
associated with decreased muscle strength, impaired physical                  Study population selection
performance, and higher frailty prevalence in aging populations
(10, 11). Furthermore, selenium contributes to mitochondrial                       This study included data from community-dwelling adults aged
function and protein synthesis in skeletal muscle, thereby helping            40–79 years, collected during the 1988–1994 (NHANES III) and
to counteract sarcopenia and physical decline (12).                           2011–2016 (NHANES) periods. These data cycles were selected due
    Previous studies indicated that selenium may affect health                to the availability of serum selenium measurements and the
outcomes by modulating inflammatory processes, which are                      information needed to assess frailty status. Participants were excluded
frequently elevated in individuals with frailty and prefrailty (8, 13,        if they were not classified as frail or prefrail, had cancer at baseline, or
14). Inflammation is a well-established contributor to the                    had no data on follow-up all-cause or cardiovascular deaths, sex, or
progression of frailty, and elevated inflammatory markers have                sample weights.
been associated with increased mortality in this population.
Selenium’s anti-inflammatory effects may offer a protective
mechanism against the adverse outcomes associated with frailty.               Assessment of prefrailty and frailty
However, the relationship between serum selenium levels,
inflammatory status, and mortality in frail and prefrail individuals               Frailty status was assessed using the Fried Frailty Phenotype (FP).
has not been thoroughly investigated (15).                                    The Fried Frailty Phenotype evaluates physical frailty based on five
    This study aims to investigate the association between serum              criteria: unintentional weight loss; weakness or poor handgrip strength;
selenium and mortality in middle-aged and older adults with                   self-reported exhaustion; slow walking speed; and low physical activity
prefrailty or frailty, with a particular focus on the mediating role          (18). For this study, we used an adapted version of the Fried Frailty
of inflammation, using data from a large, nationally representative           Phenotype, as modified in previous NHANES studies (19). This
sample from the National Health and Nutrition Examination                     modified version is an acceptable alternative for large-scale research
Survey (NHANES) of the US.                                                    when direct physical measurement are unavailable. It include four


Frontiers in Nutrition                                                   02                                                                frontiersin.org
Chang and You                                                                                                               10.3389/fnut.2025.1560167




criteria: (1) unintentional weight loss; (2) exhaustion; (3) weakness;             Diabetes mellitus (DM) were defined based on the following
and (4) low physical activity. Participants who scored one point were         criteria, and participants meeting any of these conditions were
classified as pre-frail, while those scoring two points or more were          excluded from the study cohort: a positive response to the questions:
classified as frail.                                                          “Are you taking insulin?,” “Did a doctor tell you, you have diabetes?,”
                                                                              “Do you take pills to lower blood sugar?”; an HbA1c ≥ 6.5%; a fasting
                                                                              glucose level of ≥ 126 mg/dL; or a glucose level of ≥ 200 mg/dL during
Serum selenium levels                                                         the oral glucose tolerance test (OGTT), as recorded in the NHANES
                                                                              laboratory data.
    The laboratory procedures and quality control methods for serum                CVD history was defined based on responses to the following
selenium measurements in NHANES III and NHANES 2011–2016                      questions: whether a physician had ever diagnosed coronary heart
have been well-documented (NHANES III: https://stacks.cdc.gov/view/           disease, angina, heart attack, stroke, or congestive heart failure. Chronic
cdc/45776, NHANES 2011–2012: https://wwwn.cdc.gov/nchs/nhanes/                respiratory disease was defined as the presence of any of the following
continuousnhanes/manuals.aspx?BeginYear=2011, NHANES 2013–                    conditions: asthma, chronic bronchitis, or emphysema. Chronic kidney
2014: https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/manuals.              disease (CKD) was determined by a GFR < 60 mL/min/1.73 m2. GFR
aspx?BeginYear=2013, and NHANES 2015–2016: https://wwwn.cdc.                  was estimated from re-calibrated serum creatinine using the 4-variable
gov/nchs/nhanes/continuousnhanes/manuals.aspx?BeginYear=2015).                Modification of Diet in Renal Disease (MDRD) Study equation.
In NHANES III, atomic absorption spectrometry (AAS) was used to                    Participants’ smoking status was classified into three categories:
quantify serum selenium, while Inductively Coupled Plasma Dynamic             non-smoker, former smoker, or current smoker, based on the
Reaction Cell Mass Spectrometry (ICP-DRC-MS) was utilized for the             following criteria: non-smoker if they had smoked fewer than 100
NHANES 2011–2016 measurements. All selenium levels were                       cigarettes in their lifetime; former smoker if they had smoked more
standardized to μg/L for analysis. For NHANES 2011–2016, the data             than 100 cigarettes in their lifetime but were not currently smoking;
was derived from a one-third random sample.                                   and current smoker if they had smoked more than 100 cigarettes in
                                                                              their lifetime and were still smoking.
                                                                                   Regarding the laboratory measures, the analysis included the
All-cause mortality and CVD mortality                                         white blood cell (WBC) count, neutrophil count, platelet count, and
                                                                              lymphocyte count. We also calculated the systemic immune
     Throughout the end of 2019, the NHANES participants were                 inflammation index (SII) using these measures, with the formula as
linked to the National Death Index (NDI) death certificate data which         follows: SII = Neutrophil count × Platelet count/Lymphocyte count. SII
contains nine-cause specific death categories. This enabled further           was analyzed both as a continuous variable and as a categorical
ascertainment of both the mortality status and the underlying leading         variable based on quartiles, with high SII defined as Quartile 4 and low
cause of death. All-cause mortality was defined as deaths from any            SII defined as Quartile 1 through Quartile 3.
cause, and was the main study endpoint in this investigation. CVD
mortality was defined separately as deaths from cardiac and
cerebrovascular disease through codes: UCOD_LEADING = 001                     Statistical analysis
(‘disease of the heart’) or 005 (‘cerebrovascular disease’). More
information about the Linked Mortality Files and definition of cause               The NHANES employs a complex, multistage probability
of death are available at: https://wwwn.cdc.gov/nchs/nhanes/                  sampling design to ensure national representation. To account for this
continuousnhanes/manuals.aspx?BeginYear=2011.                                 design, we applied sampling weights (WTMEC2YR, WTPFHSD6),
                                                                              pseudo-stratum (SDMVSTRA, SDPSTRA6), and pseudo-cluster
                                                                              (SDMVPSU, SDPPSU6) variables in all analyses, following the NCHS
Covariates                                                                    guidelines. Analyses were conducted using the SURVEY procedure in
                                                                              SAS. Descriptive statistics are presented as numbers (n) and weighted
     Demographic data, including age, sex, race, education level, and         percentages (%), or as means with standard errors (SE). Group
cigarette smoking were obtained through in-person interviews                  comparisons were conducted using the Rao-Scott chi-square test for
conducted by trained NHANES interviewers using the Family and                 categorical variables and linear models for continuous variables.
Sample Person Demographics questionnaires and the Computer-                        Multivariable Cox proportional hazards models were used to
Assisted Personal Interviewing (CAPI) system (Confirmit Corp.                 assess the association between serum selenium levels and mortality,
New York, United States). Collected data were weighted according to           adjusting for variables with a p-value < 0.05 in univariable analyses,
the NHANES protocol.                                                          excluding laboratory measures and frailty status.
     BMI was obtained from the NHANES examination measurements,                    Restricted cubic spline (RCS) models with three knots (at the
calculated as body weight (kilograms) divided by height (meters               25th, 50th, and 75th percentiles) were applied to evaluate the
squared). Hypertension was defined by those who responded “yes” to            relationship between serum selenium levels and all-cause mortality as
the questions: “Were you told on two or more different visits that            well as CVD mortality. Additionally, mediation analysis was
you had hypertension, also called high blood pressure?” or “Because of        conducted to explore whether the association between serum
your (high blood pressure/hypertension), have you ever been told to           selenium levels and all-cause mortality was mediated by CVD, DM,
… take prescribed medicine?,” or with an average of three consecutive         CKD, and SII. Statistical significance was determined with a two-sided
measures of systolic blood pressure ≥ 140 mmHg, or with an average            p-value of <0.05. All analyses were conducted using SAS statistical
of three consecutive measures of diastolic blood pressure ≥ 90 mmHg.          software (version 9.4, SAS Inc., Cary, NC, United States).


Frontiers in Nutrition                                                   03                                                               frontiersin.org
Chang and You                                                                                                                       10.3389/fnut.2025.1560167




Results                                                                             age was 58.9 years, with 60.5% being female. Non-Hispanic White
                                                                                    participants made up the majority of the study population, accounting
Study population                                                                    for 73.1%. All-cause mortality rates differed significantly among the
                                                                                    groups, being highest in the lowest quartile (Q1) and decreasing as
     A total of 63,896 participants were collected from the NHANES                  selenium levels increased (p = 0.014). Although cardiovascular disease
III (1988–1994), and three study cycles of the NHANES (2011–2012,                   mortality followed a similar trend, it did not reach statistical significance.
2013–2014, and 2015–2016). From this group, 11,131 individuals aged                 Race, prevalence of diabetes mellitus (DM), cardiovascular disease
40–79 years with available serum selenium levels and frailty index                  (CVD), chronic kidney disease (CKD), neutrophil counts, and SII levels
data were included. We excluded 631 participants due to missing                     also varied significantly across the selenium quartiles, and these
information on mortality status, BMI, education level, or weight.                   variables will be accounted for in the subsequent multivariable analysis
Additionally, 8,731 participants who were neither prefrail nor frail, as            (Table 1).
well as 315 individuals with a cancer diagnosis at baseline, were
excluded. Ultimately, 1,454 participants with prefrailty or frailty were
selected for further analyses. After weighting, this sample was                     Association between serum selenium and
representative of an estimated 21,382,233 US residents (Figure 1).                  mortality in individuals with prefrailty and
                                                                                    frailty

Characteristics of the individuals with                                                  Table 2 shows the associations between serum selenium levels,
prefrailty or frailty                                                               all-cause mortality, and cardiovascular disease (CVD) mortality in
                                                                                    individuals with prefrailty and frailty. After adjusting for relevant
    Table 1 presents the characteristics of the study population, divided           confounders in the multivariable analysis, participants in the second
into three groups based on quartiles of serum selenium levels. The mean             quartile of serum selenium (aOR = 0.61, 95% CI: 0.44–0.84,




    FIGURE 1
    Flow diagram of study cohort selection (n refers to a sample size while N refers to the population size).




Frontiers in Nutrition                                                         04                                                                 frontiersin.org
Chang and You                                                                                                        10.3389/fnut.2025.1560167




TABLE 1 Characteristics of the study population according to serum selenium.

                                                                                    Serum selenium, ug/L
                                              Total         Quartile 1             Quartile 2       Quartile 3      Quartile 4
 Characteristics
                                           (n = 1,454)      (≤114.9)             (114.9–125.1)    (125.1–136.9)      (>136.9)         p-value
                                                             n = 363                n = 364          n = 361         n = 366
 Outcome

  All-cause mortality                      509 (35.3)        158 (47.5)            154 (35.7)       100 (32.0)       97 (28.8)          0.014

  Cardiovascular mortality                 193 (12.8)        56 (17.7)             55 (13.3)         47 (12.7)       35 (8.6)           0.069

 Demography

  Frailty                                                                                                                               0.067

   Pre-frailty                             1,118 (81.6)      261 (73.5)            280 (81.8)       289 (84.5)      288 (84.8)

   Frailty                                 336 (18.4)        102 (26.5)            84 (18.2)         72 (15.5)       78 (15.2)

  Age, years                                58.9 ± 0.5       60.2 ± 0.8            58.1 ± 0.9       58.5 ± 0.7      58.9 ± 0.6          0.310

   40–49                                   291 (25.8)        67 (19.4)             66 (27.1)         82 (29.0)       76 (26.5)          0.419

   50–59                                   312 (22.8)        78 (24.8)             69 (22.9)         71 (19.1)       94 (24.6)

   60–69                                   522 (31.6)        132 (32.8)            151 (33.9)       130 (33.7)      109 (26.6)

   70–79                                   329 (19.8)        86 (22.9)             78 (16.0)         78 (18.2)       87 (22.3)

  Sex                                                                                                                                   0.218

   Male                                    590 (39.5)        140 (36.0)            141 (34.4)       150 (41.9)      159 (44.2)

   Female                                  864 (60.5)        223 (64.0)            223 (65.6)       211 (58.1)      207 (55.8)

  Race                                                                                                                                 <0.001

   Non-hispanic White                      545 (73.1)        119 (65.0)            124 (72.7)       138 (73.4)      164 (79.3)

   Non-hispanic Black                      384 (11.8)        126 (19.0)            107 (13.5)        90 (9.8)        61 (6.9)

   Mexican American                         267 (4.9)         67 (5.7)              75 (4.9)         62 (4.2)        63 (4.9)

   Others                                  258 (10.2)        51 (10.3)              58 (9.0)         71 (12.6)       78 (8.9)

  BMI, kg/m    2
                                             29.6 ± 0.3       29.6 ± 0.4            28.8 ± 0.5       30.1 ± 0.5      29.7 ± 0.5          0.440

  Obesity                                  647 (41.6)        177 (44.4)            152 (38.5)       158 (44.0)      160 (39.7)          0.576

  Education level                                                                                                                       0.098

    High school or above                   768 (39.3)        206 (47.2)            202 (37.8)       175 (34.3)      185 (39.5)

    Below high school                      686 (60.7)        157 (52.8)            162 (62.2)       186 (65.7)      181 (60.5)

  Cigarette smoking                                                                                                                     0.073

   Never                                   672 (45.0)        161 (42.3)            174 (47.1)       164 (43.9)      173 (46.4)

   Former                                  437 (32.3)        107 (29.4)            94 (26.2)        115 (36.1)      121 (36.1)

   Current                                 345 (22.7)        95 (28.3)             96 (26.7)         82 (20.0)       72 (17.4)

  Hypertension                             873 (53.8)        221 (56.8)            213 (50.4)       214 (48.7)      225 (59.4)          0.194

  Chronic respiratory disease              304 (22.5)        72 (22.8)             75 (18.3)         71 (22.7)       86 (25.7)          0.328

   DM                                      466 (25.2)        115 (27.0)            124 (26.8)        93 (17.7)      134 (29.9)          0.030

   CVD                                     315 (16.5)        97 (21.3)             67 (11.7)         66 (14.5)       85 (19.0)          0.040

   CKD                                     363 (25.1)        107 (33.2)            104 (26.0)        77 (23.1)       75 (20.2)          0.030

  Laboratory measures

    WBC count, 109/L (Missing = 2)        428.2 ± 320.0     40.2 ± 24.7           426.3 ± 25.5     548.8 ± 544.1   607.0 ± 581.1        0.535

    Neutrophil count, 109/L                 4.5 ± 0.1        4.4 ± 0.2             4.3 ± 0.1         4.5 ± 0.2       4.7 ± 0.2         <0.001
   (Missing = 349)

    Platelet count, 109/L (Missing = 2)   669.3 ± 319.1     274.8 ± 25.1          671.5 ± 27.5     792.9 ± 542.3   846.7 ± 579.8        0.521

    Lymphocyte count, 10 /L9
                                           423.1 ± 320.1     35.1 ± 24.8           421.3 ± 25.5     543.8 ± 544.2   601.7 ± 581.2        0.535
   (Missing = 3)

                                                                                                                                        (Continued)




Frontiers in Nutrition                                                      05                                                      frontiersin.org
Chang and You                                                                                                                                                  10.3389/fnut.2025.1560167




TABLE 1 (Continued)

                                                                                                           Serum selenium, ug/L
                                                       Total                   Quartile 1                Quartile 2                Quartile 3               Quartile 4
 Characteristics
                                                    (n = 1,454)                (≤114.9)                (114.9–125.1)             (125.1–136.9)               (>136.9)                p-value
                                                                                n = 363                   n = 364                   n = 361                  n = 366
 SII, 109/La                                          571.7 ± 16.5              587.7 ± 28.2              518.1 ± 17.8               584.5 ± 29.1             589.1 ± 24.4            <0.001

   High (>500)                                        275 (26.4)                 58 (27.5)                 61 (22.2)                   68 (25.3)               88 (29.8)             0.428

   Low (≤500)                                         830 (73.6)                206 (72.5)                183 (77.8)                   226 (74.7)             215 (70.2)

   Missing                                                 349                      99                        120                         67                      63
SII, Systemic immune-inflammatory index; BMI, body mass index; DM, diabetes mellitus; CKD, chronic kidney disease; CKD, chronic kidney disease; WBC, white blood cell.
a
 A high SII was defined as the highest quartile (Q4), while a low SII was defined as quartiles Q1 to Q3. Continuous variables are presented as mean ± SE. Categorical variables are presented as
unweighted counts (weighted percentages).
p-values < 0.05 are shown in bold.



TABLE 2 Associations between serum selenium levels, all-cause mortality, and CVD mortality.

                                                                   All-cause mortality                                                           CVD mortality
 Multivariable analysis
                                                 aHR (95% CI)
                                                        a
                                                                                              p-value                        aHR (95% CI)
                                                                                                                                    b
                                                                                                                                                                        p-value
 Serum selenium, ug/L                              0.99 (0.98–1.01)                            0.360                           0.99 (0.97–1.00)                              0.120

   Q1                                                       Ref.                                                                        Ref.

   Q2                                              0.61 (0.44–0.84)                            0.003                           0.67 (0.39–1.16)                              0.151

   Q3                                              0.70 (0.51–0.96)                            0.026                           0.78 (0.45–1.36)                              0.384

   Q4                                              0.59 (0.36–0.99)                            0.048                           0.42 (0.19–0.92)                              0.031
HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; ref, reference; CVD, cardiovascular disease. P-values < 0.05 are shown in bold. aAdjusted for variables with a p-value <
0.05 in the univariable analysis, excluding lab measures and frailty, including age (in years), education, smoking, hypertension, DM, CVD, and CKD. bAdjusted for variables with a p-value <
0.05 in the univariable analysis, excluding lab measures and frailty, including age (in years), education, cigarette smoking, DM, CVD, and CKD.



p = 0.003), third quartile (aOR = 0.70, 95% CI: 0.51–0.96, p = 0.026),                              Discussion
and fourth quartile (aOR = 0.59, 95% CI: 0.36–0.99, p = 0.048) had
a significantly lower risk of all-cause mortality. Additionally,                                        In this study, using data from the NHANES, we investigated the
participants in the fourth quartile had a significantly reduced risk                                association between serum selenium levels and mortality in the
of CVD mortality (aOR = 0.42, 95% CI: 0.19–0.92, p = 0.031)                                         prefrail and frail elderly population. We found that, after adjusting for
(Table 2).                                                                                          confounding factors, participants with higher serum selenium levels
                                                                                                    showed a significantly reduced risk of all-cause mortality, with
                                                                                                    reductions of up to approximately 40%. Additionally, those in the
Restricted cubic spline analysis                                                                    highest quartile of serum selenium experienced about a 60% lower
                                                                                                    risk of CVD mortality compared to the lowest quartile.
    The restricted cubic spline (RCS) model revealed a significant                                      Frailty is a clinical syndrome marked by increased vulnerability to
non-linear association between selenium levels and all-cause mortality                              adverse health outcomes due to declining physiological reserves across
risk, as shown in Figure 2 (p-overall = 0.002, p for                                                multiple systems. Frail individuals are more prone to stressors like
non-linearity = 0.006). For CVD mortality, although a similar trend                                 infections or surgeries, leading to worse outcomes such as falls,
was observed, it did not reach statistical significance (p-overall = 0.379,                         hospitalization, and disability (20). Though commonly linked to
p for non-linearity = 0.298) (Figure 2).                                                            aging, it can occur at any adult stage. While more prevalent in older
                                                                                                    adults, frailty affects 4–10% of middle-aged individuals (45–64 years),
                                                                                                    with higher rates seen in those with chronic disease, obesity, or lower
Mediation analysis                                                                                  socioeconomic status (21). On the other hand, proper nutrition has
                                                                                                    been shown to help reverse frailty by providing essential nutrients
     We further conducted mediation analysis to evaluate whether the                                such as proteins, vitamins (D, B12), and minerals, all of which support
protective association between a high serum selenium level (quartile                                muscle strength, bone health, and overall physical function (22, 23).
4 vs. quartile 1) and all-cause mortality was mediated through chronic                                  Current evidence suggests that selenium levels are closely
disease including DM, CVD, and CKD, as well as body’s systemic                                      associated with mortality risk across different populations. A meta-
inflammation status (surrogated by SII). The results revealed that                                  analysis by Xiang et al. (14) found that low circulating selenium was
while selenium had a significant direct effect on all-cause mortality                               linked to a higher risk of cardiovascular and all-cause mortality in the
(p < 0.001), the mediation effects through DM, CVD, CKD, or                                         general population, with pooled risk ratios of 1.36 and 1.35,
systemic inflammation status did not reach statistical significance                                 respectively. This highlights the detrimental effects of selenium
(p > 0.05) (Figures 3a–d).                                                                          deficiency on survival outcomes. In individuals with type 2 DM, a


Frontiers in Nutrition                                                                         06                                                                               frontiersin.org
Chang and You                                                                                                                  10.3389/fnut.2025.1560167




    FIGURE 2
    RCS models of the association between serum selenium (unweighted) and mortality outcomes. (a) All-cause mortality and (b) cardiovascular mortality.
    A significant non-linear association was observed between serum selenium levels and all-cause mortality (p for non-linearity = 0.006). However, no
    significant non-linear relationship was found for cardiovascular mortality (p for non-linearity = 0.297).




study by Qiu et al. (24) demonstrated that higher selenium levels were            biomarker for mortality risk. While no studies have specifically
significantly associated with reduced risks of both all-cause and heart           focused on the prefrail and frail populations, making direct
disease mortality, with the highest quartile of selenium concentration            comparisons difficult, our study indicates that the reduced mortality
showing a 31% lower risk of all-cause mortality. Similarly, Zhu et al.            risk associated with higher selenium levels in these groups is even
(25) reported that in CKD patients, higher serum selenium levels were             greater than that observed in the DM population and is comparable
associated with a lower risk of all-cause and CVD mortality, with                 to the effect size seen in CKD patients. This underscores the potential
hazard ratios of 0.684 and 0.513, respectively, for the highest quartiles.        importance of selenium for vulnerable populations.
Similarly, a study by Anadón Ruiz et al. (26) in end-stage renal disease               Beyond its potential impact on frailty, selenium has been studied
(ESRD) patients on dialysis found that low plasma selenium levels                 for its role in managing other inflammatory diseases. For instance, a
(<63 μg/L) were linked to a nearly threefold increase in the risk of              randomized, double-blind, placebo-controlled clinical trial conducted
all-cause mortality, independent of other clinical markers. Collectively,         by Khazdouz et al. investigated selenium supplementation in patients
these studies underscore the importance of maintaining adequate                   with mild-to-moderate ulcerative colitis, an inflammatory bowel
selenium levels for improving survival outcomes across different                  disease. The study reported that selenium administration (oral
populations and conditions, reinforcing selenium’s role as a potential            selenomethionine capsule, 200 mcg/day) led to clinical improvement


Frontiers in Nutrition                                                       07                                                             frontiersin.org
Chang and You                                                                                                                         10.3389/fnut.2025.1560167




    FIGURE 3
    Mediation analysis results. The estimated proportion of the association between serum selenium levels (quartile 4 vs. quartile 1) and all-cause mortality
    mediated by: (a) Diabetes mellitus (DM), (b) cardiovascular disease (CVD), (c) chronic kidney disease (CKD), and (d) systemic inflammation index (SII).
    The model was adjusted for variables with p < 0.05 in the univariable analysis, excluding laboratory measures, frailty, DM, CVD, and CKD. Covariates
    included age (in years), education level, cigarette smoking, and hypertension. IE: Adjusted hazard ratio for the indirect effect. DE: Adjusted hazard ratio
    for the direct effect. Proportion of mediation: Calculated as log (IE)/log (DE + IE).




and remission, highlighting its anti-inflammatory properties in                      findings from clinical trials offer a less optimistic view. A systematic
gastrointestinal disorders (27). In the context of rheumatoid arthritis,             review and meta-analysis of randomized controlled trials (RCTs) by
a randomized clinical trial implemented by Zamani et al. found that                  Jenkins et al. (13) found no significant effect of selenium
selenium supplementation (200 mcg/day) resulted in a modest but                      supplementation alone on cardiovascular or all-cause mortality. The
clinically relevant improvement in rheumatoid arthritis biomarkers                   dosage of selenium from included RCTs ranged from 50 to 200
such as erythrocyte sedimentation rate (ESR) and anti-cyclic                         mcg/day, regardless of other supplement exposure like vitamin C,
citrullinated peptide (anti-CCP) antibodies. This suggests a potential               zinc, etc. The benefits were only observed when selenium was
role for selenium in modulating inflammatory responses in                            included as part of antioxidant mixtures, which showed a modest
autoimmune conditions (28). Furthermore, a review research by                        reduction in mortality risk. This contrast between the strong
Barchielli illustrated selenium’s involvement in various pathologies,                associations in observational studies and the more limited effects
including its anti-inflammatory effects in conditions like Hashimoto’s               seen in clinical trials suggests that the protective role of selenium
thyroiditis and other autoimmune diseases. The review emphasized                     might be more complex, possibly influenced by interactions with
selenium’s capacity to reduce oxidative stress and modulate immune                   other nutrients or factors that observational designs may not fully
responses, contributing to its therapeutic potential in inflammatory                 account for. Besides, the Nutritional Prevention of Cancer (NPC)
disorders (29). These findings underscore selenium’s broader                         RCT-designed study administered 200 micrograms of selenium
significance in managing inflammatory diseases, reinforcing the                      daily to participants and observed a significant reduction in total
importance of adequate selenium intake for overall health and                        cancer incidence. However, increasing the dose to 400 mcg per day
disease prevention.                                                                  did not confer additional benefits, suggesting a plateau effect at the
    On the other hand, while observational studies suggest a strong                  200 mcg dosage (30). The NPC study reported a decrease in lung,
association between selenium levels and reduced mortality risk,                      colon, and prostate cancers with 200 mcg of daily selenium


Frontiers in Nutrition                                                          08                                                                  frontiersin.org
Chang and You                                                                                                               10.3389/fnut.2025.1560167




supplementation. However, there was an observed increase in                    Clinical implications
nonmelanoma skin cancer risk, highlighting the complexity of
selenium’s effects on different cancer types (30). Moreover, cisplatin,            Clinically, selenium status may serve as a potential biomarker for
a platinum-based chemotherapy used for various cancers, lowers                 mortality risk in pre-frail and frail populations. Routine selenium
selenium levels in hair and serum, though the clinical relevance               supplementation should be approached cautiously until further
remains unclear (31, 32). Small studies suggest selenium may                   evidence from interventional studies becomes available.
reduce cisplatin-induced toxicity (33), but a Cochrane Review
found insufficient evidence to confirm its benefit in mitigating
chemotherapy side effects (34).                                                Future direction
     Selenium supplementation is typically safe and well-tolerated
when maintained within recommended dosages. The tolerable upper                    Given the significant association identified between higher serum
intake level (UL) for selenium, established at 400 mcg per day for             selenium levels and reduced all-cause and cardiovascular mortality,
adults, serves as a critical threshold to prevent adverse effects (35).        future studies should prioritize confirming these findings through
Excessive intake beyond this limit has been associated with selenosis,         well-designed prospective and interventional trials. Specifically, RCTs
a condition marked by a spectrum of symptoms including                         in prefrail and frail populations are warranted to determine the causal
gastrointestinal discomfort, alopecia, brittle nails, and neurological         impact of selenium supplementation on mortality and functional
impairments (35, 36).                                                          outcomes. Additionally, research should explore optimal selenium
     Importantly, previous studies have not clarified whether the              dosing strategies, considering baseline nutritional status, age, sex,
protective effect of higher selenium levels on mortality is mediated           comorbidities, and genetic polymorphisms in selenoprotein
by factors such as chronic diseases like CVD, DM, or CKD. Our                  expression. Mechanistic studies are also needed to elucidate the
study additionally evaluated these potential mediating mechanisms;             molecular pathways through which selenium modulates inflammatory
however, the findings did not demonstrate statistically significant            responses and oxidative stress in frail states. Moreover, longitudinal
mediation effects of CVD, DM, CKD, or inflammation status (as                  analyses capturing dynamic changes in selenium levels, inflammatory
indicated by SII) on the association between higher selenium levels            biomarkers, and frailty progression could provide valuable insights
and reduced mortality. Nevertheless, human studies in the                      into the temporal relationship and therapeutic windows for
literature have shown that individuals with higher selenium levels             intervention. Finally, given global dietary variations, population-
have lower markers of systemic inflammation, including CRP, IL-6,              specific research is essential to tailor selenium-based strategies to
and TNF-α. For example, A very recent meta-analysis demonstrated               diverse nutritional and healthcare contexts.
that intravenous selenium supplementation significantly reduces
CRP and IL-6 plasma concentrations. However, it also showed an
unexpected increase in TNF-α levels (37). Another recent study                 Strengths and limitations
reported that selenium supplementation can have promising effects
by alterations of inflammatory markers for critically ill                           This study has several strengths. It uses data from the NHANES,
patients (38).                                                                 which provides a large, nationally representative sample of the
     Previous studies exploring underlying biological mechanisms may           U.S. population. The inclusion of participants from two NHANES
offer additional insights. Selenium’s role in reducing chronic                 cycles (NHANES III and NHANES 2011–2016) allows for a
inflammation, a key driver of frailty and mortality, is supported by           comprehensive analysis across different time periods, increasing the
experimental evidence. Selenoproteins, such as glutathione                     generalizability of the findings. Additionally, the study employs
peroxidases (GPXs) and thioredoxin reductases (TXNRDs), are                    rigorous statistical methods, including multivariable Cox proportional
integral to neutralizing oxidative stress and regulating inflammatory          hazards models, restricted cubic spline analysis, and mediation
pathways (39). In animal models, selenoprotein deficiency leads to             analysis, to explore the complex relationship between serum selenium,
increased susceptibility to inflammation and oxidative stress, which           inflammation, and mortality. By examining a wide range of covariates,
can drive chronic conditions like atherosclerosis and insulin                  such as demographic data, lifestyle factors, and health conditions, the
resistance—key comorbidities of frailty (29). Cell experiments also            analysis controls for potential confounding variables, enhancing the
support this mechanism. In macrophage cell lines, selenium                     validity of the results. The study also uses a standardized and well-
supplementation has been shown to inhibit the NF-κB signaling                  validated method to assess frailty status, allowing for accurate
pathway, a key regulator of pro-inflammatory gene expression, by               classification of participants into prefrail and frail groups.
enhancing the activity of selenoproteins like GPXs. The NF-κB                       However, the study has some limitations. The observational
pathway is responsible for the transcription of pro-inflammatory               design limits the ability to establish causal relationships between
cytokines, and its inhibition by selenium leads to a reduction in              serum selenium levels and mortality. Although mediation analysis was
cytokine production and inflammation (40).                                     used to explore the role of inflammation, other unmeasured factors,
     In summary, the interplay between selenium, inflammation,                 such as dietary habits, genetic variations, or long-term lifestyle
chronic disease, frailty, and mortality may be more complex than               changes, might influence both selenium levels and mortality risk.
previously understood or than initially hypothesized. This emphasizes          Additionally, serum selenium was measured only once for each
the need for further mechanistic and prospective studies to clarify            participant, which may not fully capture long-term selenium status.
how selenium’s anti-oxidative and anti-inflammatory effects                    The use of a modified Fried Frailty Phenotype, adapted for large-scale
contribute to improved long-term survival in pre-frail and                     research, may not be as precise as direct physical measurements.
frail populations.                                                             Lastly, the study is based on data from U.S. adults, which may limit the


Frontiers in Nutrition                                                    09                                                             frontiersin.org
Chang and You                                                                                                                                         10.3389/fnut.2025.1560167




applicability of the findings to populations with different dietary                           Author contributions
selenium intake or genetic backgrounds. Despite these limitations, this
study provides valuable insights into the potential role of selenium in                           C-PC: Conceptualization, Data curation, Formal analysis,
mortality risk among frail and prefrail individuals.                                          Funding acquisition, Supervision, Validation, Visualization, Writing –
                                                                                              original draft, Writing – review & editing. C-HY: Investigation,
                                                                                              Methodology, Project administration, Resources, Software, Writing –
Conclusion                                                                                    review & editing.

     In conclusion, this study demonstrates that high serum selenium
levels are independently associated with a reduced risk of CVD                                Funding
mortality and all-cause mortality in middle-aged and older adults
with prefrailty or frailty. Importantly, our findings also identify                               The author(s) declare that no financial support was received for
systemic inflammation as a predominant mediator in this association.                          the research and/or publication of this article.
While our findings underscore the relevance of serum selenium in
mortality risk, further research, particularly interventional studies, is
necessary to clarify causal mechanisms and evaluate the potential role                        Conflict of interest
of selenium in public health strategies targeting aging and
frail populations.                                                                                The authors declare that the research was conducted in the
                                                                                              absence of any commercial or financial relationships that could
                                                                                              be construed as a potential conflict of interest.
Data availability statement
     The original contributions presented in the study are included in                        Generative AI statement
the article/supplementary material, further inquiries can be directed
to the corresponding author.                                                                       The authors declare that no Gen AI was used in the creation of
                                                                                              this manuscript.

Ethics statement
                                                                                              Publisher’s note
    Ethical approval was not required for the study involving
humans in accordance with the local legislation and institutional                                 All claims expressed in this article are solely those of the authors
requirements. Written informed consent to participate in this study                           and do not necessarily represent those of their affiliated organizations,
was not required from the participants or the participants’ legal                             or those of the publisher, the editors and the reviewers. Any product
guardians/next of kin in accordance with the national legislation                             that may be evaluated in this article, or claim that may be made by its
and the institutional requirements.                                                           manufacturer, is not guaranteed or endorsed by the publisher.



References
  1. Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med.            10. van Dronkelaar C, van Velzen A, Abdelrazek M, van der Steen A, Weijs PJM,
(2011) 27:1–15. doi: 10.1016/j.cger.2010.08.009                                               Tieland M. Minerals and sarcopenia; the role of calcium, Iron, magnesium, phosphorus,
                                                                                              potassium, selenium, sodium, and zinc on muscle mass, muscle strength, and physical
  2. Goel AN, Lee JT, Gurrola JG II, Wang MB, Suh JD. The impact of frailty on
                                                                                              performance in older adults: a systematic review. J Am Med Dir Assoc. (2018) 19:6–11.e3.
perioperative outcomes and resource utilization in sinonasal cancer surgery.
                                                                                              doi: 10.1016/j.jamda.2017.05.026
Laryngoscope. (2020) 130:290–6. doi: 10.1002/lary.28006
                                                                                                11. Wang P, Chen B, Huang Y, Li J, Cao D, Chen Z, et al. Selenium intake and multiple
  3. Goldfarb M, Bendayan M, Rudski LG, Morin JF, Langlois Y, Ma F, et al. Cost of
                                                                                              health-related outcomes: an umbrella review of meta-analyses. Front Nutr. (2023)
cardiac surgery in frail compared with nonfrail older adults. Can J Cardiol. (2017)           10:1263853. doi: 10.3389/fnut.2023.1263853
33:1020–6. doi: 10.1016/j.cjca.2017.03.019
                                                                                                12. Wesolowski LT, Semanchik PL, White-Springer SH. Beyond antioxidants:
  4. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, onder G, Fried LP. Frailty:                selenium and skeletal muscle mitochondria. Front Vet Sci. (2022) 9:1011159. doi:
implications for clinical practice and public health. Lancet. (2019) 394:1365–75. doi:        10.3389/fvets.2022.1011159
10.1016/S0140-6736(19)31786-6
                                                                                                13. Jenkins DJA, Kitts D, Giovannucci EL, Sahye-Pudaruth S, Paquette M, Blanco
 5. Zhang L, Zeng X, He F, Huang X. Inflammatory biomarkers of frailty: a review. Exp         Mejia S, et al. Selenium, antioxidants, cardiovascular disease, and all-cause mortality: a
Gerontol. (2023) 179:112253. doi: 10.1016/j.exger.2023.112253                                 systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr.
  6. Pan C, Cao N. Patterns of social isolation and low social support and frailty            (2020) 112:1642–52. doi: 10.1093/ajcn/nqaa245
trajectories among Chinese older adults. J Appl Gerontol. (2023) 42:2325–34. doi:               14. Xiang S, Dai Z, Man C, Fan Y. Circulating selenium and cardiovascular or all-cause
10.1177/07334648231194508                                                                     mortality in the general population: a Meta-analysis. Biol Trace Elem Res. (2020)
  7. Anand A, Syamala TS, Kanchan Sk MI, Bhatt N. Understanding frailty, functional           195:55–62. doi: 10.1007/s12011-019-01847-8
health and disability among older persons in India: a decomposition analysis of gender          15. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular
and place of resident. J Res Health Sci. (2020) 20:e00484. doi: 10.34172/jrhs.2020.20         disease, and frailty. Nat Rev Cardiol. (2018) 15:505–22. doi: 10.1038/s41569-018-0064-2
  8. Hariharan S, Dharmaraj S. Selenium and selenoproteins: it's role in regulation of          16. Terry AL, Chiappa MM, McAllister J, Woodwell DA, Graber JE. Plan and
inflammation. Inflammopharmacology. (2020) 28:667–95. doi: 10.1007/s10787-020-00690-x         operations of the National Health and nutrition examination survey, august 2021-august
                                                                                              2023. Vital Health Stat 1. (2024) 66:1–32. doi: 10.15620/cdc:151927
  9. Rocourt CR, Cheng WH. Selenium supranutrition: are the potential benefits of
chemoprevention outweighed by the promotion of diabetes and insulin resistance?                17. National Center for Health Statistics. Plan and operation of the Third National
Nutrients. (2013) 5:1349–65. doi: 10.3390/nu5041349                                           Health and Nutrition Examination Survey, 1988–94. Vital Health Stat 1. (1994) 32:1–407.




Frontiers in Nutrition                                                                   10                                                                           frontiersin.org
Chang and You                                                                                                                                            10.3389/fnut.2025.1560167




  18. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty            29. Barchielli G, Capperucci A, Tanini D. The role of selenium in pathologies: an
in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. (2001)                 updated review. Antioxidants. (2022) 11:251. doi: 10.3390/antiox11020251
56:M146–57. doi: 10.1093/gerona/56.3.M146
                                                                                                   30. Reid ME, Duffield-Lillico AJ, Slate E, Natarajan N, Turnbull B, Jacobs E, et al. The
  19. Kurnat-Thoma EL, Murray MT, Juneau P. Frailty and determinants of health                   nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutr Cancer.
among older adults in the United States 2011-2016. J Aging Health. (2022) 34:233–44.             (2008) 60:155–63. doi: 10.1080/01635580701684856
doi: 10.1177/08982643211040706
                                                                                                   31. Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer
  20. Doody P, Lord JM, Greig CA, Whittaker AC. Frailty: pathophysiology, theoretical            in women receiving chemotherapy. Gynecol Oncol. (2004) 93:320–7. doi:
and operational definition(s), impact, prevalence, management and prevention, in an              10.1016/j.ygyno.2003.12.013
increasingly economically developed and ageing world. Gerontology. (2023) 69:927–45.
doi: 10.1159/000528561                                                                             32. Vernie LN, de Goeij JJM, Zegers C, de Vries M, Baldew GS, McVie JG. Cisplatin-
                                                                                                 induced changes of selenium levels and glutathione peroxidase activities in blood of
  21. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty        testis tumor patients. Cancer Lett. (1988) 40:83–91. doi: 10.1016/0304-3835(88)90265-0
in middle-aged and older adults and its association with multimorbidity and mortality:
a prospective analysis of 493 737 UK biobank participants. Lancet Public Health. (2018)            33. Hu YJ, Chen Y, Zhang YQ, Zhou MZ, Song XM, Zhang BZ, et al. The protective
3:e323–32. doi: 10.1016/S2468-2667(18)30091-4                                                    role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer
                                                                                                 patients. Biol Trace Elem Res. (1997) 56:331–41. doi: 10.1007/BF02785304
  22. Feart C. Nutrition and frailty: current knowledge. Prog Neuro-Psychopharmacol
Biol Psychiatry. (2019) 95:109703. doi: 10.1016/j.pnpbp.2019.109703                                34. Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy,
                                                                                                 radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev. (2006)
  23. Yoshida S, Shiraishi R, Nakayama Y, Taira Y. Can nutrition contribute to a                 2006:Cd005037. doi: 10.1002/14651858.CD005037.pub2
reduction in sarcopenia, frailty, and comorbidities in a super-aged society? Nutrients.
(2023) 15:991. doi: 10.3390/nu15132991                                                            35. Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds.
                                                                                                 Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids.
  24. Qiu Z, Geng T, Wan Z, Lu Q, Guo J, Liu L, et al. Serum selenium concentrations             Washington (DC): National Academies Press (US) (2000).
and risk of all-cause and heart disease mortality among individuals with type 2 diabetes.
Am J Clin Nutr. (2022) 115:53–60. doi: 10.1093/ajcn/nqab241                                         36. Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch‐Ernst K‐I, Knutsen HK,
                                                                                                 et al. Scientific opinion on the tolerable upper intake level for selenium. EFSA J. (2023)
  25. Zhu D, Zhong Q, Lin T, Song T. Higher serum selenium concentration is associated           21:e07704. doi: 10.2903/j.efsa.2023.7704
with lower risk of all-cause and cardiovascular mortality among individuals with chronic
kidney disease: a population-based cohort study of NHANES. Front Nutr. (2023)                       37. Gholizadeh M, Khalili A, Roodi PB, Saeedy SAG, Najafi S, Keshavarz
10:1127188. doi: 10.3389/fnut.2023.1127188                                                       Mohammadian M, et al. Selenium supplementation decreases CRP and IL-6 and
                                                                                                 increases TNF-alpha: a systematic review and meta-analysis of randomized controlled
  26. Anadón Ruiz A, Martín Jiménez E, Bermejo-Barrera P, Lozano R, Seijas VME.                  trials. J Trace Elem Med Biol. (2023) 79:127199. doi: 10.1016/j.jtemb.2023.127199
Selenium and all-cause mortality in end-stage renal disease. Retrospective observational
cohort study. J Ren Nutr. (2020) 30:484–92. doi: 10.1053/j.jrn.2020.02.006                         38. Mahmoodpoor A, Faramarzi E, Reyhanifard A, Shamekh A, Nikanfar S, Azizi-
                                                                                                 Zeinalhajlou A, et al. The effects of selenium supplementation on inflammatory markers
  27. Khazdouz M, Daryani NE, Cheraghpour M, Alborzi F, Hasani M, Ghavami SB,                    in critically ill patients. SN Appl Sci. (2022) 4:326. doi: 10.1007/s42452-022-05208-4
et al. The effect of selenium supplementation on disease activity and immune-
inflammatory biomarkers in patients with mild-to-moderate ulcerative colitis: a                    39. Zoidis E, Seremelis I, Kontopoulos N, Danezis G. Selenium-dependent antioxidant
randomized, double-blind, placebo-controlled clinical trial. Eur J Nutr. (2023)                  enzymes: actions and properties of Selenoproteins. Antioxidants. (2018) 7:66. doi:
62:3125–34. doi: 10.1007/s00394-023-03214-9                                                      10.3390/antiox7050066
  28. Zamani B, Taghvaee F, Akbari H, Mohtashamian A, Sharifi N. Effects of selenium               40. Wolfram T, Weidenbach LM, Adolf J, Schwarz M, Schädel P, Gollowitzer A, et al.
supplementation on the indices of disease activity, inflammation and oxidative stress in         The trace element selenium is important for redox signaling in Phorbol Ester-
patients with rheumatoid arthritis: a randomized clinical trial. Biol Trace Elem Res.            differentiated THP-1 macrophages. Int J Mol Sci. (2021) 22:60. doi:
(2024) 202:1457–67. doi: 10.1007/s12011-023-03782-1                                              10.3390/ijms222011060




Frontiers in Nutrition                                                                      11                                                                           frontiersin.org

```
